Home
Solution
Overview
Market Access Platform
Analytical Services
Experience
User Capabilities
Use Case
About
Our Story
Company
Management
Press
Careers
FAQ
Insights & Research
Blog
Articles
Webinars
Events
Contact
SIGN IN

Context Matters

Home
Solution
Overview
Market Access Platform
Analytical Services
Experience
User Capabilities
Use Case
About
Our Story
Company
Management
Press
Careers
FAQ
Insights & Research
Blog
Articles
Webinars
Events
Contact
SIGN IN
Anand Gan
January 30, 2015
HTA, Healthcare, Data

Context Matters Featured in pharmaphorum

Anand Gan
January 30, 2015
HTA, Healthcare, Data
 

Does Real World Evidence Matter in Health Technology Assessments?

Both pharma companies and health technology assessment (HTA) agencies have been considering real world evidence (RWE) as a complementary source of data, but to what extent is it actually used? And is it worth the attention?

 
Read the article on pharmaphorum
Newer PostContext Matters Featured in Pharmaceutical Commerce
Older PostSovaldi and the Politics of High Priced Drugs: Are We Asking the Right Questions?

BLOG

ARTICLES

WEBINARS

EVENTS


topics

  • Clinical Trials
  • Data
  • HTA
  • Healthcare
  • In the News
  • Pharma
  • Regulatory
  • Reimbursement
  • Technology

SIGN UP FOR NEWS

Name *
Name
Thank you!

FOLLOW US

  • RT @totalbiopharma: Come to Track 4 now to hear Rachel Jao @ContextMatters & Ruth Howells, DRG give an interesting talk on "Is there bi… https://t.co/wCIl6wbFyb
    about a month ago
  • Do #HTA agencies evaluate Brand+Brand combos differently? Our experts are evaluating the data. #PPMA2018 https://t.co/CH2ITnyF0d
    about a month ago
  • Stop by for a live demo! #PPMA2018 @Terrapinn https://t.co/uwSXT48QoF
    about a month ago
  • Classification of #drugs can have massive #clinical and #economic effects for #pharma. https://t.co/rYSoFoto0A
    about 4 months ago
  • IP23:CM data sets the stage for an in-depth chat of patient involvement with reps from @CADTH_ACMTS, @eupatients, @Pharmerit #ISPORGlasgow
    about 5 months ago
  • Budget Impact Test: a new special consideration process for NICE (to be reviewed in 2020) #ISPORglasgow
    about 5 months ago
  • NICE decision making has some flexibility, especially in end of life treatment #ISPORGlasgow https://t.co/s96eY4ALp9
    about 5 months ago
  • an important difference between ICER and NICE is the environment for HTA #ISPORGlasgow https://t.co/NRjJADyLXw
    about 5 months ago
  • like NICE, ICER has special populations and circumstances #ISPORGlasgow https://t.co/QFCk3wYhO2
    about 5 months ago
  • We are toasting the union of Context Matters with @DRGinsights . #ISPORGlasgow booth 313 https://t.co/B783YQRNkF
    about 5 months ago

Context Matters, (A Decision Resources Group Company)  provides health economics data and technology solutions designed to help biopharmaceutical organizations gain market access with optimally valued therapies.

PRIVACY & COOKIES | TERMS OF USE | RESEARCH PRIVACY

Back to Top
Home
Solution
Experience
About
Insights & Research
Contact

SIGN UP FOR NEWS

Name *
Name
Thank you!
 
 
 

©2018 Context Matters (A Decision Resources Group Company). All rights reserved.